EN
EN
BioNova Submits Investigational New Drug Application for BN104 for the Treatment of Acute Leukemia in China
May 24, 2023
BioNova today announced that it has submitted an investigational new drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia to the China National Medical Products Administration (NMPA).